| Nov 6 |
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 5 |
Entrada Therapeutics GAAP EPS of -$0.35 beats by $0.44, revenue of $19.57M beats by $7.69M
|
| Nov 5 |
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 5 |
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
|
| Oct 9 |
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
|
| Sep 24 |
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
|
| Sep 6 |
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
|
| Aug 18 |
Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically
|
| Aug 15 |
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
|
| Aug 14 |
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
|
